D-Wave’s Q1 Sales Disappoint, but Backlog Shows 2026 Could Be Huge
D-Wave revenue missed but loss smaller; bookings surged to $33.4M from big deals.
Already have an account? Sign in.
D-Wave revenue missed but loss smaller; bookings surged to $33.4M from big deals.
BMO Capital gives Trevi Therapeutics an Outperform rating and $36 target, citing strong potential for Haduvio as a first-in-class treatment for chronic cough in idiopathic pulmonary fibrosis.
Analyst forecasts show Intel and Samsung struggling to close the gap on A16 and N2 technology.
Genuine Parts lowered its 2026 profit outlook amid weaker consumer demand. CEO Will Stengel denied rumors of a rival acquiring its automotive business.